Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07115745 · ClinicalTrials.gov registry record · Phase 1
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
A Phase 1 study of Refractory Autoimmune Diseases, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT07115745 is a Phase 1 study of Refractory Autoimmune Diseases that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 125 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT07115745, a Phase 1 study of Refractory Autoimmune Diseases, is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Tocilizumab
- GENETIC BMS-986515
Study Locations (20)
Other
- Local Institution - 0039 - Porto Alegre
- Local Institution - 0038 - São Paulo
- Revmatologicky ustav - Prague
- Charité - Universitaetsmedizin Berlin - Campus Bejnamin Franklin - Berlin
- Universitätsklinikum Carl Gustav Carus an der TU Dresden - Dresden
- Local Institution - 0031 - Hamburg
- Hadassah Medical Center - Jerusalem
Massachusetts
- Local Institution - 0041 - Boston
North Carolina
- Local Institution - 0037 - Durham
New South Wales
- Local Institution - 0007 - Camperdown
Queensland
- Local Institution - 0008 - Brisbane
Victoria
- Local Institution - 0013 - Clayton
Estado de Bahia
- Local Institution - 0040 - Salvador
Praha 5
- Local Institution - 0004 - Prague
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-09-04 |
| Est. Completion | 2030-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07115745
The ClinicalTrials.gov registry entry for NCT07115745 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Refractory Autoimmune Diseases appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT07115745 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07115745 about?
NCT07115745 is a clinical study titled "A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases". The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.
What is the current status of trial NCT07115745?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2025-09-04. Estimated completion is 2030-08-16.
What conditions does trial NCT07115745 study?
This clinical trial studies the following conditions: Refractory Autoimmune Diseases.
What interventions are being tested in trial NCT07115745?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Tocilizumab (DRUG), BMS-986515 (GENETIC).
Who is sponsoring clinical trial NCT07115745?
This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07115745 being conducted?
This trial has 20 study locations across Massachusetts, North Carolina, New South Wales, Queensland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.